Filing Flows

Filing Flows › Companies › BridgeBio Pharma › Cash flow

BridgeBio Pharma cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$44.5M in Q3 2026 · −$370M over twelve months

Operating cash flow−$44.2M
Capital spending−$290K
Free cash flow−$44.5M
Cash conversion cycle75 days

Analysis

In Q3 2026, BridgeBio Pharma generated −$44.2M of operating cash flow and spent $290K on capital projects, leaving free cash flow of −$44.5M. That is $65.6M more than in Q3 2025 (−$110M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$369M; the largest uses were operating cash flow ($369M), buybacks ($253M), taxes on employees’ shares ($20.9M); besides operations, cash came from other financing ($1.5B), shares issued ($46.9M); the cash balance rose by $890M.

Operating cash flow was −$44.2M against net income of −$60.5M. The largest differences: receivables −$121M, payables +$61.0M, stock-based pay +$39.9M.

Its cash conversion cycle was 75 days (receivables 82 + inventory 253 − payables 260).

Free cash flow

BridgeBio Pharma: free cash flow by quarterBridgeBio Pharma: free cash flow by quarter−$195MQ4 2024−$199MQ1 2025−$81.3MQ2 2025−$110MQ3 2025−$56.5MQ4 2025−$197MQ1 2026−$71.5MQ2 2026−$44.5MQ3 2026
Operating cash flow less capital spending.
BridgeBio Pharma: operating cash flow against capital spendingBridgeBio Pharma: operating cash flow against capital spendingOperating cash flowCapital spending−$195M$47KQ4 2024−$199M$0Q1 2025−$80.7M$594KQ2 2025−$110M$470KQ3 2025−$56.4M$33KQ4 2025−$197M$69KQ1 2026−$71.1M$443KQ2 2026−$44.2M$290KQ3 2026
Latest (Q3 2026): Operating cash flow −$44.2M, Capital spending $290K.

Capital allocation, year by year

BridgeBio Pharma: where the cash came from (up) and went (down), by fiscal yearBridgeBio Pharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$498MFY2021: Net borrowing $332MFY2021: Shares issued $16.6MFY2021: Capital spending −$13.2MFY2021: Buybacks −$200M$349MFY2021FY2022: Operating cash flow −$419MFY2022: Net borrowing −$20.5MFY2022: Shares issued $5.5MFY2022: Asset sales $10.0MFY2022: Capital spending −$4.8M$15.5MFY2022FY2023: Operating cash flow −$528MFY2023: Shares issued $456MFY2023: Capital spending −$1.3M$456MFY2023FY2024: Operating cash flow −$521MFY2024: Net borrowing −$497MFY2024: Shares issued $318MFY2024: Capital spending −$933K$318MFY2024FY2025: Operating cash flow −$446MFY2025: Net borrowing −$459MFY2025: Shares issued $27.7MFY2025: Capital spending −$1.1MFY2025: Buybacks −$48.3M$27.7MFY2025
Over these 5 years operating cash flow totalled −$2.4B; the largest uses were operating cash flow ($2.4B) and net borrowing ($976M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.5B
Debt$2.6B
Net debt$1.1B
Due within a year$40.6M
Cash runway4.2 years

BridgeBio Pharma is burning cash: its operations consume cash, a free cash flow of −$370M a year at the current rate against $1.5B of cash and investments: a runway of about 4.2 years; $40.6M of debt also comes due within a year, which the cash covers before any new financing.

BridgeBio Pharma: debt maturities by year (FY2025)BridgeBio Pharma: debt maturities by year (FY2025)$40.6MYear 1$584MYear 2$26.9MYear 3$766MYear 4$10.1MYear 5$580MAfter year 5
Principal due in each year as disclosed in the annual report, against $1.5B of cash and investments now.

Where the cash came from and went

BridgeBio Pharma: sources (+) and uses (−) of cash, Q3 2026BridgeBio Pharma: sources (+) and uses (−) of cash, Q3 2026Other financing$905MCash drawn (+) / kept (−)−$855MOperating cash flow−$44.2MBuybacks−$42.5MOther investing$36.9MShares issued$5.9MTaxes on employees’ shares−$5.1MCapital spending−$290K
BridgeBio Pharma: sources (+) and uses (−) of cash, TTM to Q3 2026BridgeBio Pharma: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$1.5BCash drawn (+) / kept (−)−$890MOperating cash flow−$369MBuybacks−$253MShares issued$46.9MTaxes on employees’ shares−$20.9MOther investing−$1.8MCapital spending−$835KPartners$600K

From profit to cash

BridgeBio Pharma: net income to operating cash flow, Q3 2026BridgeBio Pharma: net income to operating cash flow, Q3 2026Net income−$60.5MDepreciation & amortization$1.1MStock-based pay$39.9MOther non-cash$731KReceivables−$121MInventory−$7.5MPayables$61.0MEmployee-related liabilities$16.7MDeferred revenue−$2.3MPrepaid and other assets−$6.6MOther liabilities−$4.0MOperating cash flow−$44.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20268225326075
Q2 202686260170175
Q1 20268027029655
Q4 20257629131256
Q3 20257430031459
Q2 202579277668-312
Q1 20254667633-520

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$44.2M−$290K−$42.5M—$5.9M−$855M−$44.5M
Q2 2026−$71.1M−$443K−$128M—$5.2M$202M−$71.5M
Q1 2026−$197M−$69K−$82.5M—$22.6M−$310M−$197M
Q4 2025−$56.4M−$33K——$13.2M$73.0M−$56.5M
Q3 2025−$110M−$470K——$4.8M$106M−$110M
Q2 2025−$80.7M−$594K——$7.2M−$208M−$81.3M
Q1 2025−$199M—−$48.3M−$918M$2.5M$141M−$199M
Q4 2024−$195M−$47K——$2.8M−$275M−$195M

BridgeBio Pharma: income statement and cash flow

BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%. The chart follows the revenue to costs, profit and cash.

BridgeBio Pharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.